Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Asymptomatic azygos vein overflow in a young patient with primary mediastinal seminoma.

Di Liello R, Sparano F, Iacovino ML, Viscardi G, Della Corte CM, Ronchi A, Sabetta RL, Fasano M, Vicidomini G, Reginelli A, Ciardiello F, Morgillo F.

Thorac Cancer. 2019 Sep 30. doi: 10.1111/1759-7714.13170. [Epub ahead of print]

PMID:
31568668
2.

Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study.

Di Liello R, Ciaramella V, Barra G, Venditti M, Della Corte CM, Papaccio F, Sparano F, Viscardi G, Iacovino ML, Minucci S, Fasano M, Ciardiello F, Morgillo F.

ESMO Open. 2019 Aug 19;4(4):e000536. doi: 10.1136/esmoopen-2019-000536. eCollection 2019.

3.

Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lung cancer.

Sen T, Della Corte CM, Milutinovic S, Cardnell RJ, Diao L, Ramkumar K, Gay CM, Stewart CA, Fan Y, Shen L, Hansen RJ, Strouse B, Hedrick MP, Hassig CA, Heymach JV, Wang J, Byers LA.

J Thorac Oncol. 2019 Aug 27. pii: S1556-0864(19)30692-6. doi: 10.1016/j.jtho.2019.08.009. [Epub ahead of print]

PMID:
31470128
4.

Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures.

Della Corte CM, Barra G, Ciaramella V, Di Liello R, Vicidomini G, Zappavigna S, Luce A, Abate M, Fiorelli A, Caraglia M, Santini M, Martinelli E, Troiani T, Ciardiello F, Morgillo F.

J Exp Clin Cancer Res. 2019 Jun 13;38(1):253. doi: 10.1186/s13046-019-1257-1.

5.

Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC.

Ciaramella V, Sasso FC, Di Liello R, Corte CMD, Barra G, Viscardi G, Esposito G, Sparano F, Troiani T, Martinelli E, Orditura M, De Vita F, Ciardiello F, Morgillo F.

J Exp Clin Cancer Res. 2019 Apr 26;38(1):178. doi: 10.1186/s13046-019-1176-1.

6.

Early use of steroids affects immune cells and impairs immunotherapy efficacy.

Della Corte CM, Morgillo F.

ESMO Open. 2019 Feb 27;4(1):e000477. doi: 10.1136/esmoopen-2018-000477. eCollection 2019. No abstract available.

7.

Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis.

D'Abrosca B, Ciaramella V, Graziani V, Papaccio F, Della Corte CM, Potenza N, Fiorentino A, Ciardiello F, Morgillo F.

Sci Rep. 2019 Mar 21;9(1):4986. doi: 10.1038/s41598-019-41372-1.

8.

EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.

Martini G, Cardone C, Vitiello PP, Belli V, Napolitano S, Troiani T, Ciardiello D, Della Corte CM, Morgillo F, Matrone N, Sforza V, Papaccio G, Desiderio V, Paul MC, Moreno-Viedma V, Normanno N, Rachiglio AM, Tirino V, Maiello E, Latiano TP, Rizzi D, Signoriello G, Sibilia M, Ciardiello F, Martinelli E.

Mol Cancer Ther. 2019 Apr;18(4):845-855. doi: 10.1158/1535-7163.MCT-18-0539. Epub 2019 Mar 1.

PMID:
30824612
9.

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.

Sen T, Rodriguez BL, Chen L, Corte CMD, Morikawa N, Fujimoto J, Cristea S, Nguyen T, Diao L, Li L, Fan Y, Yang Y, Wang J, Glisson BS, Wistuba II, Sage J, Heymach JV, Gibbons DL, Byers LA.

Cancer Discov. 2019 May;9(5):646-661. doi: 10.1158/2159-8290.CD-18-1020. Epub 2019 Feb 18.

PMID:
30777870
10.

Evading the STING: LKB1 Loss Leads to STING Silencing and Immune Escape in KRAS-Mutant Lung Cancers.

Della Corte CM, Byers LA.

Cancer Discov. 2019 Jan;9(1):16-18. doi: 10.1158/2159-8290.CD-18-1286.

PMID:
30626603
11.

Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint era.

Della Corte CM, Gay CM, Byers LA.

Cancer. 2019 Feb 15;125(4):496-498. doi: 10.1002/cncr.31863. Epub 2019 Jan 8. No abstract available.

PMID:
30620399
12.

ILK and SHP2 expression identify a poor prognostic cohort of EGFR-mutant lung cancer.

Della Corte CM, Gay CM, Byers LA, Morgillo F.

EBioMedicine. 2019 Jan;39:5-6. doi: 10.1016/j.ebiom.2018.12.008. Epub 2018 Dec 13. No abstract available.

13.

HGF/MET and the Immune System: Relevance for Cancer Immunotherapy.

Papaccio F, Della Corte CM, Viscardi G, Di Liello R, Esposito G, Sparano F, Ciardiello F, Morgillo F.

Int J Mol Sci. 2018 Nov 14;19(11). pii: E3595. doi: 10.3390/ijms19113595. Review.

14.

Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs.

Diana A, Franzese E, Centonze S, Carlino F, Della Corte CM, Ventriglia J, Petrillo A, De Vita F, Alfano R, Ciardiello F, Orditura M.

Curr Oncol Rep. 2018 Aug 20;20(10):76. doi: 10.1007/s11912-018-0726-6. Review.

PMID:
30128845
15.

Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs.

Orditura M, Della Corte CM, Diana A, Ciaramella V, Franzese E, Famiglietti V, Panarese I, Franco R, Grimaldi A, Lombardi A, Caraglia M, Santoriello A, Procaccini E, Lieto E, Maiello E, De Vita F, Ciardiello F, Morgillo F.

Breast. 2018 Oct;41:165-171. doi: 10.1016/j.breast.2018.08.002. Epub 2018 Aug 4.

PMID:
30103105
16.

Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota.

Morgillo F, Dallio M, Della Corte CM, Gravina AG, Viscardi G, Loguercio C, Ciardiello F, Federico A.

Neoplasia. 2018 Jul;20(7):721-733. doi: 10.1016/j.neo.2018.05.002. Epub 2018 May 30. Review. No abstract available.

17.

Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells.

Ciaramella V, Della Corte CM, Di Mauro C, Tomassi S, Di Maro S, Troiani T, Martinelli E, Bianco R, Cosconati S, Pierantoni R, Meccariello R, Chianese R, Ciardiello F, Morgillo F.

Oncotarget. 2018 Apr 10;9(27):19273-19282. doi: 10.18632/oncotarget.25018. eCollection 2018 Apr 10.

18.

Kisspeptin and Cancer: Molecular Interaction, Biological Functions, and Future Perspectives.

Ciaramella V, Della Corte CM, Ciardiello F, Morgillo F.

Front Endocrinol (Lausanne). 2018 Mar 27;9:115. doi: 10.3389/fendo.2018.00115. eCollection 2018. Review.

19.

Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models.

Della Corte CM, Ciaramella V, Cardone C, La Monica S, Alfieri R, Petronini PG, Malapelle U, Vigliar E, Pepe F, Troncone G, Castellone MD, Troiani T, Martinelli E, Ciardiello F, Morgillo F.

J Thorac Oncol. 2018 Jun;13(6):810-820. doi: 10.1016/j.jtho.2018.02.025. Epub 2018 Mar 8.

20.

Role and targeting of anaplastic lymphoma kinase in cancer.

Della Corte CM, Viscardi G, Di Liello R, Fasano M, Martinelli E, Troiani T, Ciardiello F, Morgillo F.

Mol Cancer. 2018 Feb 19;17(1):30. doi: 10.1186/s12943-018-0776-2. Review.

21.

Primary pleural squamous cell carcinoma: A diagnostic challenge.

Ronchi A, Cozzolino I, Montella M, Vicidomini G, Morgillo F, Della Corte CM, Franco R, Accardo M.

Cytopathology. 2018 Apr;29(2):205-207. doi: 10.1111/cyt.12498. Epub 2017 Nov 21. No abstract available.

PMID:
29159961
22.

Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells.

Napolitano S, Martini G, Martinelli E, Della Corte CM, Morgillo F, Belli V, Cardone C, Matrone N, Ciardiello F, Troiani T.

Oncotarget. 2017 Aug 2;8(47):82773-82783. doi: 10.18632/oncotarget.19797. eCollection 2017 Oct 10.

23.

Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells.

Morgillo F, Della Corte CM, Diana A, Mauro CD, Ciaramella V, Barra G, Belli V, Franzese E, Bianco R, Maiello E, de Vita F, Ciardiello F, Orditura M.

Oncotarget. 2017 Aug 22;8(44):76479-76491. doi: 10.18632/oncotarget.20385. eCollection 2017 Sep 29.

24.

Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer.

Morgillo F, Amendola G, Della Corte CM, Giacomelli C, Botta L, Di Maro S, Messere A, Ciaramella V, Taliani S, Marinelli L, Trincavelli ML, Martini C, Novellino E, Ciardiello F, Cosconati S.

J Med Chem. 2017 Sep 14;60(17):7447-7458. doi: 10.1021/acs.jmedchem.7b00794. Epub 2017 Aug 22.

PMID:
28787156
25.

Present and future of metastatic colorectal cancer treatment: A review of new candidate targets.

Martini G, Troiani T, Cardone C, Vitiello P, Sforza V, Ciardiello D, Napolitano S, Della Corte CM, Morgillo F, Raucci A, Cuomo A, Selvaggi F, Ciardiello F, Martinelli E.

World J Gastroenterol. 2017 Jul 14;23(26):4675-4688. doi: 10.3748/wjg.v23.i26.4675. Review.

26.

Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer.

Morgillo F, Fasano M, Della Corte CM, Sasso FC, Papaccio F, Viscardi G, Esposito G, Di Liello R, Normanno N, Capuano A, Berrino L, Vicidomini G, Fiorelli A, Santini M, Ciardiello F.

ESMO Open. 2017 May 2;2(2):e000132. doi: 10.1136/esmoopen-2016-000132. eCollection 2017.

27.

Implication of the Hedgehog pathway in hepatocellular carcinoma.

Della Corte CM, Viscardi G, Papaccio F, Esposito G, Martini G, Ciardiello D, Martinelli E, Ciardiello F, Morgillo F.

World J Gastroenterol. 2017 Jun 28;23(24):4330-4340. doi: 10.3748/wjg.v23.i24.4330. Review.

28.

Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.

Della Corte CM, Malapelle U, Vigliar E, Pepe F, Troncone G, Ciaramella V, Troiani T, Martinelli E, Belli V, Ciardiello F, Morgillo F.

Oncotarget. 2017 Apr 4;8(14):23020-23032. doi: 10.18632/oncotarget.15479.

29.

Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review.

Fasano M, Della Corte CM, Vicidomini G, Scotti V, Rambaldi PF, Fiorelli A, Accardo M, De Vita F, Santini M, Ciardiello F, Morgillo F.

Oncol Lett. 2016 Dec;12(6):4505-4509. doi: 10.3892/ol.2016.5279. Epub 2016 Oct 18.

30.

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence.

Troiani T, Napolitano S, Della Corte CM, Martini G, Martinelli E, Morgillo F, Ciardiello F.

ESMO Open. 2016 Sep 16;1(5):e000088. eCollection 2016. Review.

31.

Mechanisms of resistance to EGFR-targeted drugs: lung cancer.

Morgillo F, Della Corte CM, Fasano M, Ciardiello F.

ESMO Open. 2016 May 11;1(3):e000060. eCollection 2016. Review.

32.

Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.

Della Corte CM, Ciaramella V, Di Mauro C, Castellone MD, Papaccio F, Fasano M, Sasso FC, Martinelli E, Troiani T, De Vita F, Orditura M, Bianco R, Ciardiello F, Morgillo F.

Oncotarget. 2016 Jan 26;7(4):4265-78. doi: 10.18632/oncotarget.6559.

33.

SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.

Della Corte CM, Bellevicine C, Vicidomini G, Vitagliano D, Malapelle U, Accardo M, Fabozzi A, Fiorelli A, Fasano M, Papaccio F, Martinelli E, Troiani T, Troncone G, Santini M, Bianco R, Ciardiello F, Morgillo F.

Clin Cancer Res. 2015 Oct 15;21(20):4686-97. doi: 10.1158/1078-0432.CCR-14-3319. Epub 2015 Jun 29.

34.

Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy.

Fasano M, Della Corte CM, Papaccio F, Ciardiello F, Morgillo F.

J Thorac Oncol. 2015 Aug;10(8):1133-41. doi: 10.1097/JTO.0000000000000589.

35.

Vertebral carcinomatosis eleven years after advanced gastric cancer resection: A case report.

Iovino F, Orditura M, Auriemma PP, Ciorra FR, Giordano G, Orabona C, Bara F, Sergio R, Savastano B, Fabozzi A, Laterza MM, Ventriglia J, Petrillo A, Della Corte CM, DE Vita F.

Oncol Lett. 2015 Mar;9(3):1403-1405. Epub 2014 Dec 23.

36.

Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer.

Della Corte CM, Fasano M, Papaccio F, Ciardiello F, Morgillo F.

Biomedicines. 2014 Nov 25;2(4):345-358. doi: 10.3390/biomedicines2040345. Review.

37.

A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial.

Fasano M, Della Corte CM, Capuano A, Sasso FC, Papaccio F, Berrino L, Ciardiello F, Morgillo F.

Clin Lung Cancer. 2015 Jan;16(1):57-9. doi: 10.1016/j.cllc.2014.06.010. Epub 2014 Aug 17.

PMID:
25242667
38.

Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer.

Fasano M, Della Corte CM, Califano R, Capuano A, Troiani T, Martinelli E, Ciardiello F, Morgillo F.

Expert Opin Investig Drugs. 2014 Jun;23(6):809-21. doi: 10.1517/13543784.2014.902934. Epub 2014 Mar 28. Review.

PMID:
24673358
39.

Metformin in lung cancer: rationale for a combination therapy.

Morgillo F, Sasso FC, Della Corte CM, Festino L, Manzo A, Martinelli E, Troiani T, Capuano A, Ciardiello F.

Expert Opin Investig Drugs. 2013 Nov;22(11):1401-9. doi: 10.1517/13543784.2013.828691. Epub 2013 Aug 12. Review.

PMID:
23937224
40.

Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.

Morgillo F, Sasso FC, Della Corte CM, Vitagliano D, D'Aiuto E, Troiani T, Martinelli E, De Vita F, Orditura M, De Palma R, Ciardiello F.

Clin Cancer Res. 2013 Jul 1;19(13):3508-19. doi: 10.1158/1078-0432.CCR-12-2777. Epub 2013 May 21.

41.

Alcohol and risky behaviors.

Corte CM, Sommers MS.

Annu Rev Nurs Res. 2005;23:327-60. Review.

PMID:
16350769
42.

Ecologic momentary assessment of eating-disordered behaviors.

Stein KF, Corte CM.

Int J Eat Disord. 2003 Nov;34(3):349-60.

Supplemental Content

Loading ...
Support Center